Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas
Authors:
- 1 August 2014
- journal article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 343 (1-2) , 60-65
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experienceJournal of Neuro-Oncology, 2013
- Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity:in vitroandin vivostudiesExpert Opinion on Drug Delivery, 2013
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experienceNeurosurgical Review, 2010
- Biodegradable Carmustine Wafers (Gliadel) Alone or in Combination with Chemoradiotherapy: The French ExperienceAnnals of Surgical Oncology, 2010
- Risk Management in the Treatment of Malignant Gliomas with BCNU Wafer ImplantsCentral European Neurosurgery, 2010
- Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experienceCurrent Medical Research and Opinion, 2008
- Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank modelJournal of Controlled Release, 2007
- Dose Escalation of Carmustine in Surgically Implanted Polymers in Patients With Recurrent Malignant Glioma: A New Approaches to Brain Tumor Therapy CNS Consortium TrialJournal of Clinical Oncology, 2003
- Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomasJournal of Neurosurgery, 1991